Skip to main content

Request a Demo

See GxP Flow in action

By submitting, you agree to our Privacy Policy

Back to Blog
DMS Journey

DMS Journey Part 2: Bridging Solutions and Preparing for Transition

Practical strategies to strengthen your current document system while planning for a compliant DMS—including hybrid approaches that address immediate risks without overcommitting.

PharmaDoc Team
December 19, 2024
8 min read

The gap between where you are and Part 11 compliance can feel vast. But transition doesn't require a leap—it requires a bridge.

Bridging solutions aren't about delaying investment. They're about investing strategically while you prepare for systematic change. Done correctly, they reduce immediate regulatory exposure, clarify your actual requirements, and make eventual DMS implementation faster and less expensive.

The Hierarchy of Risk

Not all gaps carry equal weight. Audit trail deficiencies will draw regulatory attention faster than imperfect access management. Electronic signature weaknesses can invalidate entire record sets. Prioritize accordingly.

Address audit trails first. Implement an independent logging mechanism—a protected spreadsheet, a form submission log, or a dedicated logging service—that captures who did what, when, and why. This log must be separate from your documents and protected from casual deletion. It won't be Part 11 compliant, but it demonstrates awareness and intent.

Strengthen signature accountability next. A two-factor approval process—where approvers complete both an in-document approval block and a separate form submission requiring corporate login—creates an evidence chain that typed names alone cannot provide. The form captures verified identity, explicit intent, and system-generated timestamps. This isn't compliance; it's credible effort toward compliance.

Document your controls. Write down what tools you use, how you've configured them, what they're intended to do, and where you know they fall short. Include a risk assessment and a remediation timeline. When an auditor asks about system validation, having this documentation transforms "it's Google Drive" into "we've performed a risk-based assessment and implemented documented controls while planning transition to a validated system."

Preparing for Migration

The bridge period is also preparation time. Standardize your naming conventions across all documents—this alone can cut migration effort significantly. Convert effective documents to PDF/A for archival stability. Build a comprehensive document register with complete metadata. These aren't just good practices; they're pre-migration work that will pay dividends when transition begins.

The Discipline of Transition Planning

Set explicit transition triggers: a regulatory milestone, a document count threshold, a calendar date. Without triggers, bridges become permanent. "Good enough" calcifies into "the way we've always done it."

Use this time to understand your requirements. What workflow complexity do you actually need? How critical is training integration? What's your realistic budget? The gaps you've experienced will inform better vendor selection than any feature checklist.

Speaking to Auditors

If inspected during the bridge period, clarity serves you better than defensiveness. Explain your supplementary controls, present your documentation, and share your transition roadmap with specific timelines. Regulators distinguish between companies in conscious transition and companies hoping nobody notices.


Continue to Part 3: Implementing a Compliant DMS when you're ready to evaluate, select, and implement a system designed for pharmaceutical compliance.

Ready to Simplify Your Compliance?

See how GxPFlow can help your pharmaceutical company achieve 21 CFR Part 11 compliance with ease.

Request a Demo

See GxP Flow in action

By submitting, you agree to our Privacy Policy

Read More Articles